These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34252682)

  • 1. Unravelling the therapeutic potential of marine drugs as SARS-CoV-2 inhibitors: An insight from essential dynamics and free energy landscape.
    Rampogu S; Gajula RG; Lee G; Kim MO; Lee KW
    Comput Biol Med; 2021 Aug; 135():104525. PubMed ID: 34252682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marine natural compounds as potents inhibitors against the main protease of SARS-CoV-2-a molecular dynamic study.
    Khan MT; Ali A; Wang Q; Irfan M; Khan A; Zeb MT; Zhang YJ; Chinnasamy S; Wei DQ
    J Biomol Struct Dyn; 2021 Jul; 39(10):3627-3637. PubMed ID: 32410504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigating the antiviral therapeutic potentialities of marine polycyclic lamellarin pyrrole alkaloids as promising inhibitors for SARS-CoV-2 and Zika main proteases (Mpro).
    Pereira F; Bedda L; Tammam MA; Alabdullah AK; Arafa R; El-Demerdash A
    J Biomol Struct Dyn; 2024 May; 42(8):3983-4001. PubMed ID: 37232419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based identification of SARS-CoV-2 main protease inhibitors from anti-viral specific chemical libraries: an exhaustive computational screening approach.
    Bhowmick S; Saha A; Osman SM; Alasmary FA; Almutairi TM; Islam MA
    Mol Divers; 2021 Aug; 25(3):1979-1997. PubMed ID: 33844135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential anti-viral activity of approved repurposed drug against main protease of SARS-CoV-2: an
    Mahanta S; Chowdhury P; Gogoi N; Goswami N; Borah D; Kumar R; Chetia D; Borah P; Buragohain AK; Gogoi B
    J Biomol Struct Dyn; 2021 Jul; 39(10):3802-3811. PubMed ID: 32406317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of potential plant-based inhibitor against viral proteases of SARS-CoV-2 through molecular docking, MM-PBSA binding energy calculations and molecular dynamics simulation.
    Gogoi B; Chowdhury P; Goswami N; Gogoi N; Naiya T; Chetia P; Mahanta S; Chetia D; Tanti B; Borah P; Handique PJ
    Mol Divers; 2021 Aug; 25(3):1963-1977. PubMed ID: 33856591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational screening for potential drug candidates against the SARS-CoV-2 main protease.
    Silva Andrade B; Ghosh P; Barh D; Tiwari S; José Santana Silva R; Rodrigues de Assis Soares W; Silva Melo T; Santos Freitas A; González-Grande P; Sousa Palmeira L; Carlos Junior Alcantara L; Giovanetti M; Góes-Neto A; Ariston de Carvalho Azevedo V
    F1000Res; 2020; 9():. PubMed ID: 33447372
    [No Abstract]   [Full Text] [Related]  

  • 10. Screening Malaria-box compounds to identify potential inhibitors against SARS-CoV-2 M
    Ahamad S; Kanipakam H; Birla S; Ali MS; Gupta D
    Eur J Pharmacol; 2021 Jan; 890():173664. PubMed ID: 33131721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
    Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A
    PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection of SARS-CoV-2 main protease inhibitor using structure-based virtual screening.
    Hakami AR; Bakheit AH; Almehizia AA; Ghazwani MY
    Future Med Chem; 2022 Jan; 14(2):61-79. PubMed ID: 34814706
    [No Abstract]   [Full Text] [Related]  

  • 13. Structure-based virtual screening suggests inhibitors of 3-Chymotrypsin-Like Protease of SARS-CoV-2 from Vernonia amygdalina and Occinum gratissimum.
    Gyebi GA; Elfiky AA; Ogunyemi OM; Ibrahim IM; Adegunloye AP; Adebayo JO; Olaiya CO; Ocheje JO; Fabusiwa MM
    Comput Biol Med; 2021 Sep; 136():104671. PubMed ID: 34332348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants -
    Shree P; Mishra P; Selvaraj C; Singh SK; Chaube R; Garg N; Tripathi YB
    J Biomol Struct Dyn; 2022 Jan; 40(1):190-203. PubMed ID: 32851919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reconstruction of the unbinding pathways of noncovalent SARS-CoV and SARS-CoV-2 3CLpro inhibitors using unbiased molecular dynamics simulations.
    Noroozi Tiyoula F; Aryapour H
    PLoS One; 2022; 17(2):e0263251. PubMed ID: 35139108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tafenoquine and its derivatives as inhibitors for the severe acute respiratory syndrome coronavirus 2.
    Chen Y; Yang WH; Chen HF; Huang LM; Gao JY; Lin CW; Wang YC; Yang CS; Liu YL; Hou MH; Tsai CL; Chou YZ; Huang BY; Hung CF; Hung YL; Wang WJ; Su WC; Kumar V; Wu YC; Chao SW; Chang CS; Chen JS; Chiang YP; Cho DY; Jeng LB; Tsai CH; Hung MC
    J Biol Chem; 2022 Mar; 298(3):101658. PubMed ID: 35101449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sterenin M as a potential inhibitor of SARS-CoV-2 main protease identified from MeFSAT database using molecular docking, molecular dynamics simulation and binding free energy calculation.
    Prajapati J; Patel R; Goswami D; Saraf M; Rawal RM
    Comput Biol Med; 2021 Aug; 135():104568. PubMed ID: 34174757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein-Ligand Docking Simulations with AutoDock4 Focused on the Main Protease of SARS-CoV-2.
    de Azevedo Junior WF; Bitencourt-Ferreira G; Godoy JR; Adriano HMA; Dos Santos Bezerra WA; Dos Santos Soares AM
    Curr Med Chem; 2021; 28(37):7614-7633. PubMed ID: 33781188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Computer-Aided Drug Design Approach to Predict Marine Drug-Like Leads for SARS-CoV-2 Main Protease Inhibition.
    Gaudêncio SP; Pereira F
    Mar Drugs; 2020 Dec; 18(12):. PubMed ID: 33322052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19.
    Joshi T; Sharma P; Joshi T; Pundir H; Mathpal S; Chandra S
    Mol Divers; 2021 Aug; 25(3):1665-1677. PubMed ID: 32602074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.